A clinical trial led by the University of Glasgow has found that a wearable mini-pump can safely discharge heart failure patients from hospital nearly a week ahead of schedule, allowing them to complete treatment at home.

Wearable Device Could Transform Heart Failure Care Beyond Hospital Walls

Heart failure is one of the most expensive and persistent challenges facing the NHS. Patients admitted with acute decompensation, the dangerous build-up of fluid that leaves people breathless and exhausted, typically spend nine to ten days in hospital receiving intravenous diuretics before they are well enough to go home. It is a cycle that repeats itself. Around one in four patients is readmitted within 30 days, and the condition accounts for more than one million hospital bed days in England every year.

Now, findings from a major UK clinical trial suggest that a wearable subcutaneous drug delivery device could safely cut that hospital stay by nearly five days, without increasing complications or deterioration in patient outcomes. The results, presented at the European Society of Cardiology Heart Failure Congress 2026 in Barcelona, represent a meaningful shift in what home care technology can achieve for people with complex cardiovascular conditions.

What The SUBCUT HF II Trial Found

The trial, led by researchers at the University of Glasgow and conducted across 20 UK hospitals, enrolled 172 patients with worsening heart failure caused by fluid overload. Participants were randomised to receive either conventional intravenous diuretic therapy in hospital or a novel wearable device that delivers a skin-friendly subcutaneous formulation of furosemide, the diuretic most commonly used in this setting via a small pump worn on the body.

The device works in a manner broadly comparable to insulin pumps already widely used in diabetes management. Patients received initial stabilisation and device training in hospital before being discharged to complete their treatment independently at home, with support from family members where needed.

The key finding was a reduction in hospital stay of approximately five days in the device group, with no reported increase in adverse outcomes or worsening illness among those who completed treatment at home. Researchers also noted high levels of patient acceptance and ease of use, a critical factor in any home care technology that asks patients or carers to take on clinical tasks outside a supervised setting.

Dr Ross Campbell, Clinical Senior Lecturer at the University of Glasgow, said the study demonstrated that patients could safely manage heart failure treatment outside hospital settings while maintaining recovery outcomes comparable to conventional care.

Why This Matters For The UK Care Sector

The implications for NHS community services and home care providers are significant. Reducing hospital length of stay for heart failure patients does not simply free up beds, it shifts the site of care to the home and community, which carries both opportunity and responsibility for those working in digital health, remote monitoring, and community nursing.

Any meaningful expansion of this approach would require healthcare systems to think carefully about how patients are supported once they leave hospital. Community health technology from remote monitoring platforms to connected care devices would need to be in place to flag deterioration and maintain clinical oversight. The device itself addresses the pharmacological challenge; the infrastructure around it determines whether home-based care is genuinely safe at scale.

This is territory the NHS has been moving into cautiously but consistently. NHS England’s virtual ward programme, which has expanded significantly since 2022, is designed precisely to support patients with acute conditions including heart failure to receive hospital-level care in their own homes, monitored by clinical teams using digital health tools. The SUBCUT HF II findings suggest there is now a validated pharmacological component that could sit within that infrastructure.

A Gap In Community Heart Failure Support

Despite the growth of virtual wards, heart failure remains one of the conditions where the gap between hospital-based and community-based care is most acute. Many community nursing teams lack the resources or training to manage intravenous therapies, which is precisely why patients have historically remained in hospital for the full course of diuretic treatment. A subcutaneous wearable approach removes that barrier.

For social care providers and integrated care systems designing home-first pathways, the device represents a meaningful addition to the toolkit. It does not require clinical staff to administer intravenous treatment in the home; it delegates a carefully managed therapeutic process to the patient, supported by technology.

Industry And Policy Context

The trial arrives at a moment when both policymakers and care technology suppliers are under pressure to demonstrate that care at home and in communities can be both safe and cost-effective. NHS IMPACT, the productivity programme running across integrated care systems, has identified elective recovery and reducing avoidable admissions as central priorities. Heart failure readmissions sit squarely in the frame.

The wider UK care sector has seen accelerating investment in digital tools designed to support remote care from AI-powered triage platforms to sensor-based falls detection and medication management devices. Wearable therapeutics devices that do not simply monitor but actively deliver treatment represent the next frontier.

That shift is already visible in diabetes care, where wearable insulin pumps and continuous glucose monitors have fundamentally changed how patients manage a lifelong condition. The SUBCUT HF II trial suggests something similar may now be achievable for one of the most common and costly acute presentations in cardiology.

What Comes Next

The trial findings will need to be followed by larger-scale implementation studies and health economic analysis before wearable subcutaneous diuretic therapy becomes part of standard clinical pathways. Questions remain about which patient groups are most suitable, how remote monitoring should be configured to support home treatment, and what level of community nursing involvement is appropriate.

Nevertheless, the data is sufficiently compelling to expect significant interest from NHS integrated care boards, community health technology suppliers, and the growing number of virtual ward providers developing clinical models for heart failure.

For care providers, technology companies, and NHS commissioners working to build sustainable home-first models, the SUBCUT HF II trial is a useful reminder that innovation in care at home is not only about monitoring and coordination. Sometimes, it is about redesigning the treatment itself.